PART I Overview We are a leading provider of ophthalmic disease management solutions in North America, and were founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye di...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001493152-26-008562 | EDGAR | 77K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000925 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001493152-24-010518 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001493152-23-008718 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001493152-22-006525 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001493152-21-005583 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001493152-20-003862 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001493152-19-003188 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001493152-18-003095 | EDGAR | — |
| 2017-03-21 | 2016-12-31 | 0001493152-17-002687 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001493152-25-021562 | EDGAR | 32K words |
| 2025-08-11 | 2025-06-30 | 0001641172-25-022980 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001641172-25-009263 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045295 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001493152-24-030575 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001493152-24-018902 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040563 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001493152-23-027361 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001493152-23-016414 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032076 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001493152-22-021769 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001493152-22-012261 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001493152-26-013199 | EDGAR | 18K words |
| 2026-03-24 | 0001493152-26-012389 | EDGAR | — |
| 2026-03-24 | 0001493152-26-012279 | EDGAR | — |
| 2026-03-10 | 0001493152-26-009452 | EDGAR | — |
| 2026-03-02 | 0001493152-26-008552 | EDGAR | — |
| 2026-02-02 | 0001493152-26-004635 | EDGAR | — |
| 2025-11-18 | 0001493152-25-023988 | EDGAR | — |
| 2025-11-10 | 0001493152-25-021555 | EDGAR | — |
| 2025-10-06 | 0001493152-25-017007 | EDGAR | — |
| 2025-09-29 | 0001493152-25-015878 | EDGAR | — |
384 total filings indexed. 352 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001360214 |
| Ticker | HROW |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.harrow.com |
| Listed | 2007-04-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report